Member Info for Jatw

Of course this is just my fantasy CEO musings....

Is Not very reliable.....sorry for the buyers over 400p today...still hold on you should be profit shortly.

the US BOD will need to put the US company first ahead of making distributions to the shareholders....that may be the case today if the regulator wants another course of action, however the Pru will lose the ability to have its way when the directors consider other owners interests.....then rating agencies will start to treat the US separately from the group....it will get messy.

1 transparency....HCM publishes its expected pipeline news p51/2 of the corporate presentation
2 it achieves its milestones
3 seems to be building effective relations with Chinese and US regulators
4 is an ethical and effective organisation

Pru will have the option of establishing a majority or minority position depending on how much is floated....(maybe some new money raised and a few hundred million for Pru).
Either way, Pru will lose control over dividend policy and the cash remitted from the US.
A clean break like MNG is best.

Timetable is not stated, but 18-24 months to submit the NDA and approval at the end of 2022.

2023 is going to be a BIG year with the top 3 drugs all selling well and extended applications following on...

Forget the rumour of a potential bid that did not come to anything.
It seems trading has been positive and the rejuvenation of proleukin is coming along nicely.
Management has made regular acquisitions so I am sure they will looking for another soon up to 500m. ...then a merger with another 1.5 to 2bn organisation and a move to FTSE

My view of share buy backs is that they are an almost guaranteed win for traders .buy today and in a few days time offload to the company agent....when the programme ends the volume falls away and with it the SP. benefits the board by rising EPS even when profits are flat.....collect the eps based bonus, rinse and repeat.
I would take a dividend (in a tax advantaged vehicle) any day. I can think of several high profile buy backs that a few months after they stop have added no value.

GSK is good value under £16.00
Split is still 12-24 months away, more interested in pipeline news this year.

Articles are all past tense and sound as if no offer is likely.
Market reaction tomorrow more likely down than up.

Thanks for pointing it out. Not a Daily Mail reader myself.
A PE enquiry at 10.50 to 11gbp.
Not sure that is a knockout bid...they need to offer a lot more premium....£14 would likely be enough.

Clin is not like cobham - that was on its knees as a result of bad contracts. Clin has a strong future to look forward to now that Iovance seems to be working for Proleukin.

Let’s see what the FY results bring

Don’t ignore the reverse situation of using the 350 oncology sales force to market others drugs.
They intend to scale this up to 900. While the pipeline may grow in coming years, if you can put extra volume through the same distribution any sales commissions will fall straight to the bottom line.

Is there a more volatile share this year in the FTSE?
It seems to be plus or minus 5% every few days.

Week 2 was a loss Mon-thur of 110p
Cumulative loss of 10
Buy and hold +110

CH said all options are on the table.....they have to choose any partners wisely as they will be a constraint and will have their own agendas.

That said licensing the drug to markets for a large upfront payment and royalty may be attractive.
Going it alone will probably mean a slower path to a lower peak sales.

They will give us an answer but not for a while.

Strange start today. HK peers up 3%, Pru down 2%. Is the US really doing that poorly?

It is a large deal....but only 50% can flow up the group structure. It should defer any fund raising ideas by 6 months or increase the value if the JV is sold

Life insurers go up and down with the market.....only more so.
Long run generally a good investment, although some are better than others. In my view LGEN is a quality company. It has a strong franchise in the products it offers and targets a growing demographic of boomers needing retirement income.
There is much uncertainty ahead but as long as there is no mass extinction of large companies, LG should survive and in the long term prosper.

More likely to see US or European consolidation rather than US+Europe combo. The “losing” side will block the deal.
There could be some pooling of subsidiary interests eg VIIV is a 3 way JV To save costs on similar products and gain monopolistic pricing power.
Also these are so big they need to be mostly share based mergers without much cash paid....is that attractive to Shareholders in these times?

Sadly they don’t appear to have updated their valuation model and the valuation is still “ahead of numerous catalysts later this year”. While it is prudent to wait for NDA approval, they need to start upping the success % and actually estimating the target market and profitability for suru and Savo.

That is something the company should highlight more.....what is the estimated value of the target market and what market share do they think they can realistically achieve...it might help show the relative values of their candidates further back in the pipeline.